ICCM News
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. SitesPR NewswireCAESAREA, Israel, Oct. 20, 2026 CAESAREA, Israel, Oct. 20...
PR Newswire
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. SitesPR NewswireCAESAREA, Israel, Oct. 20, 2026 CAESAREA, Israel, Oct. 20...
PR Newswire
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026 IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026PR NewswireCAESAREA, Israel, October 13, 2026Scientific...
PR Newswire
IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SitePR NewswireCAESAREA, Israel, Oct. 6, 2026CAESAREA...
PR Newswire
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Zacks
IceCure Medical Receives Regulatory Approval to Market ProSense in China
IceCure Medical Receives Regulatory Approval to Market ProSense in China IceCure Medical Receives Regulatory Approval to Market ProSense in China PR Newswire CAESAREA, Israel, Sept. 10, 2026 CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ --IceCure Medical Ltd.(NASDAQ: ICCM) ("IceCure," "IceCure...
PR Newswire
IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands
IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands IceCure Signs Exclusive Distribution Agreement for ProSense Cryoablation Systems in the Netherlands PR Newswire CAESAREA, Israel, Aug. 24, 2026 Agreement expands ProSense commercialization in the...
PR Newswire
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation PR Newswire CAESAREA, Israel, Aug. 20, 2026 Patients are expected to enroll in the...
PR Newswire
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation PR Newswire CAESAREA, Israel, Aug. 13, 2026 New review by...
PR Newswire
IceCure Medical Ltd Q2 2026 Earnings Call Summary
IceCure Medical Ltd Q2 2026 Earnings Call Summary...
Yahoo! Finance: News